<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289229</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125101839</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-CELGENEUS-028-22393-13013323</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>2</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130121</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130121</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-CELGENE-028-22393-13013323</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>CA-CELGENE-028-21880-10071167</linkreportnumb>
    </linkedreport>
    <linkedreport>
      <linkreportnumb>CA-CELGENE-028-21880-12100557</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportertitle>Dr</reportertitle>
      <reportergivename>Vishal</reportergivename>
      <reporterfamilyname>Kukreti</reporterfamilyname>
      <reporterorganization>Princess Margaret Hospital</reporterorganization>
      <reporterstreet>610 Univeristy Ave., 5-227</reporterstreet>
      <reportercity>Toronto</reportercity>
      <reporterstate>ON</reporterstate>
      <reporterpostcode>M5G 2M9</reporterpostcode>
      <reportercountry>CA</reportercountry>
      <qualification>1</qualification>
      <studyname lang="en">EVCT-999999-25#Istodax Special Access Program in Canada</studyname>
      <sponsorstudynumb>RM-SAP-CAN-001</sponsorstudynumb>
      <observestudytype>2</observestudytype>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>W-Y</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19540204</patientbirthdate>
      <patientsex>1</patientsex>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10061758</patientepisodename>
        <patientmedicalstartdateformat>610</patientmedicalstartdateformat>
        <patientmedicalstartdate>201108</patientmedicalstartdate>
        <patientmedicalenddateformat>610</patientmedicalenddateformat>
        <patientmedicalenddate>201201</patientmedicalenddate>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10061758</patientepisodename>
        <patientmedicalstartdateformat>610</patientmedicalstartdateformat>
        <patientmedicalstartdate>201203</patientmedicalstartdate>
        <patientmedicalenddateformat>610</patientmedicalenddateformat>
        <patientmedicalenddate>201204</patientmedicalenddate>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10059043</patientepisodename>
        <patientmedicalstartdateformat>610</patientmedicalstartdateformat>
        <patientmedicalstartdate>201205</patientmedicalstartdate>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10061819</patientepisodename>
      </medicalhistoryepisode>
      <patientdeath>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">DEATH</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ISTODAX</medicinalproduct>
        <obtaindrugcountry>CA</obtaindrugcountry>
        <drugauthorizationnumb>22,393</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10034623</drugindication>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>ROMIDEPSIN</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Unknown</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>ISTODAX</medicinalproduct>
        <obtaindrugcountry>CA</obtaindrugcountry>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028483</drugindication>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>ISTODAX</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness>
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Unknown</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">DEATH

RM-SAP-CAN-001 (CANADA):  Istodax Special Access Program in Canada 

Initial information received on 21Jan2013 from a Healthcare Professional reporting the death of a 58 year old male patient who received Romidepsin for the treatment of Peripheral Large T Cell Lymphoma (PTCL) and Mycosis Fungoides diagnosed in Jun2011. Therapy dates, dosages and frequency for Romidepsin were unknown. Lot number and expiration date were not provided. The patient was reported to be on the Istodax Special Access Program in Canada. The proposed treatment plan was for the patient to receive Romidepsin 14mg/m2 on days 1, 8, 15 of a 28 day cycle times 12 cycles, however it is unknown if that was the dosage the patient actually received (to be confirmed). Relevant medical history included CHOP chemotherapy (/Aug/2011 - /Jan/2012),GDP therapy (/Mar/2012 - /Apr/2012), autologous stem cell transplant (/May/2012). In Aug2012, patient diagnosed with relapsed disease. 

It was reported that the patient died on an unknown date. The cause of death was not provided. No further information was provided. The reporter assessed the causal relationship between Istodax and the patient's death as unknown. Additional information will be requested from the prescriber.</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and DEATH suggest that a causal relationship is possible, but underlying disease or co morbidities could provide an alternative explanation.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
